Today’s cyclodextrin is about their potential in osteoporosis.
This paper was published by University of Delaware who found that after treating bone marrow stromal cells with methyl-β-cyclodextrin, a disruptor of cellular endocytosis, bone morphogenetic protein (BMP) signaling is restored in 15-month-old mice, as shown by von Kossa assays.
MβCD has the potential to restore BMP receptor type Ia function, and the BMP signaling pathway offers a promising avenue for future OP therapies.
Congrats to Daniel Halloran, Venu Pandit, Kelechi Blessing Chukwuocha and Anja Nohe for their great work!
